Holen Sie sich die Stockscreener-App
2.50
1.21%
0.03
Schlusskurs vom Vortag:
$2.47
Offen:
$2.5
24-Stunden-Volumen:
762.27K
Relative Volume:
0.49
Marktkapitalisierung:
$424.85M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-236.30M
KGV:
-1.7085
EPS:
-1.4633
Netto-Cashflow:
$-208.07M
1W Leistung:
-5.30%
1M Leistung:
-27.75%
6M Leistung:
+47.06%
1J Leistung:
+119.30%
1-Tages-Spanne:
$2.465
$2.615
1-Wochen-Bereich:
$2.41
$2.63
52-Wochen-Spanne:
$0.611
$3.65
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Firmenname
Neumora Therapeutics Inc
Sektor
Branche
Telefon
(857) 760-0900
Adresse
260 ARSENAL PLACE, SUITE 1, WATERTOWN
Compare NMRA vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
2.50 | 419.75M | 0 | -236.30M | -208.07M | -1.4633 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-17 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2026-01-12 | Eingeleitet | Leerink Partners | Outperform |
| 2025-12-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-10-27 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-09-16 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-04-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-03-10 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-07 | Herabstufung | Stifel | Buy → Hold |
| 2025-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-10-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-07-08 | Eingeleitet | Mizuho | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-10 | Eingeleitet | BofA Securities | Buy |
| 2023-10-10 | Eingeleitet | Guggenheim | Buy |
| 2023-10-10 | Eingeleitet | JP Morgan | Overweight |
| 2023-10-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-10-10 | Eingeleitet | Stifel | Buy |
| 2023-10-10 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Neumora Therapeutics Inc Aktie (NMRA) Neueste Nachrichten
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the ... - Bluefield Daily Telegraph
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
Neumora Therapeutic (NMRA.US) will release its earnings report on March 30. - Moomoo
If You Invested $1,000 in Neumora Therapeutics Inc (NMRA) - Stock Titan
Neumora Therapeutics stock jumps, analyst sees upside in Alzheimer's treatment - MSN
NMRA SEC FilingsNeumora Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Neumora Therapeutics (NMRA) positioned to capitalize on blockbuster opportunity - MSN
Quarterly Trades: Is Neumora Therapeutics Inc forming a breakout pattern2026 Investor Takeaways & Daily Profit Maximizing Tips - baoquankhu1.vn
RBC sees upside potential in Neumora Therapeutics (NMRA) - MSN
Neumora reports promising Phase 1b results in Alzheimer’s agitation - MSN
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Short Interest Down 13.7% in February - MarketBeat
Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026 - The Manila Times
Neuropsych Drugmaker Wants Out Of Investors' IPO Data Suit - Law360
Neumora Therapeutics (NASDAQ:NMRA) Stock Price Up 8.2%What's Next? - MarketBeat
Neumora Therapeutics (NMRA) Positioned to Capitalize on Blockbuster Opportunity - Bitget
Neumora Therapeutics Inc (NMRA) Sheds More Light on Phase 1b Study of NMRA-511 - Finviz
Esperion Therapeutics Inc (ESPR) Strengthens Business Outlook Amid Strategic Agreements - Bitget
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
GSA Capital Partners LLP Cuts Stake in Neumora Therapeutics - National Today
Neumora Therapeutics (NASDAQ:NMRA) Shares Gap DownTime to Sell? - MarketBeat
GSA Capital Partners LLP Cuts Position in Neumora Therapeutics, Inc. $NMRA - MarketBeat
Winners Losers: Will Neumora Therapeutics Inc benefit from geopolitical trends2025 Market WrapUp & Reliable Entry Point Trade Alerts - baoquankhu1.vn
AlphaCore Capital LLC Has $1.16 Million Stock Holdings in Neumora Therapeutics, Inc. $NMRA - MarketBeat
Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA), Larimar Therapeutics (LRMR) and Cigna (CI) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN) and Xenon (XENE) - The Globe and Mail
Neumora Therapeutics (NMRA) Projected to Post Earnings on Monday - MarketBeat
Neumora cut to Hold at Stifel after J&J’s VENTURA exit - MSN
Can Neumora Therapeutics Inc. stock withstand economic slowdownJuly 2025 Snapshot & Weekly Setup with High ROI Potential - mfd.ru
Risk Recap: Is Telomir Pharmaceuticals Inc stock a buy or sellFed Meeting & Smart Allocation Stock Tips - baoquankhu1.vn
Neumora Therapeutics CFO Milligan sells $5119 in shares By Investing.com - Investing.com Australia
Neumora Therapeutics CFO Milligan sells $5119 in shares - Investing.com
Top Neumora Executives Quietly Cash Out in Coordinated Stock Sell-Off - TipRanks
Insider Sell Alert: Michael Milligan Sells Shares of Neumora The - GuruFocus
Neumora Therapeutics (NASDAQ:NMRA) Insider Paul Berns Sells 9,819 Shares - MarketBeat
Insider Selling: Neumora Therapeutics (NASDAQ:NMRA) Insider Sells 6,165 Shares of Stock - MarketBeat
Trading Recap: Will Neumora Therapeutics Inc stock go up in YEARTake Profit & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Neumora Therapeutics advances in novel brain-penetrant therapies - Traders Union
Neumora Therapeutics (NASDAQ:NMRA) Hits New 12-Month High Following Analyst Upgrade - MarketBeat
William Blair upgrades Neumora Therapeutics (NMRA) - MSN
William Blair Upgrades Neumora Therapeutics (NMRA) - Nasdaq
Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment - Benzinga
Neumora Therapeutics Shares Rise After William Blair Upgrade - marketscreener.com
Neumora Therapeutics (NASDAQ:NMRA) Shares Gap Up After Analyst Upgrade - MarketBeat
William Blair Upgrades Neumora Therapeutics to Outperform From Market Perform - marketscreener.com
Neumora Therapeutics (NASDAQ:NMRA) Rating Increased to Outperform at William Blair - MarketBeat
Will Neumora Therapeutics Inc. stock go up in YEAR2025 Trading Recap & Fast Entry Momentum Trade Alerts - mfd.ru
Finanzdaten der Neumora Therapeutics Inc-Aktie (NMRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):